SVS @ STS: Examining the Potential of Cell Therapy

SVS @ STS: Sharing Common Ground for Cardiovascular Problems


1:30 p.m. – 3:30 p.m.

Room 350DEF

The use of cell therapy for treating critical limb ischemia, refractory angina, and heart failure is just one of the links between cardiac and vascular surgery that will be reviewed Monday during an annual session planned by STS and the Society for Vascular Surgery.

“In years past, we have learned a lot by listening to each other and not practicing in vacuums. Vascular surgeons bring interesting insights to problems we treat and vice versa,” said cardiac and vascular surgeon Keith B. Allen, MD, co-moderator of the session with vascular surgeon Jason T. Lee, MD, of the Stanford University School of Medicine in Palo Alto, Calif.

Cell therapy is an obvious area for the two groups to have a meeting of the minds. Studies released in the past 18 months have shown vascular surgeons its potential to treat critical limb ischemia. At the same time, cardiac surgeons have learned more about using cell therapy to manage heart failure and refractory angina.

“Here we are with two disciplines treating three areas and using the same compounds. We thought this would be a nice way to cross-pollinate,” said Dr. Allen, of St. Luke’s Mid American Heart Institute and the University of Missouri–Kansas City.

The first two presentations will look at areas where both specialties often work. A cardiac surgeon will offer management options for arch pathology, and a vascular surgeon will share tips on management of the left subclavian artery during aortic endovascular repair.

“They will talk about different approaches to managing the left subclavian artery because those often involve a bypass,” Dr. Allen said. “Vascular surgeons don’t do the big operations for the arch, but it is important for them to hear how cardiac surgeons manage that. Cardiac surgeons should hear about how to manage the head vessels or brachiocephalic vessels, particularly the left subclavian.”

Two talks will review cell therapies for “no option” patients—those with critical limb ischemia and those with medically refractory angina.

“Some are proprietary, some are autologous, and some are factor-derived,” Dr. Allen said of therapies for critical limb ischemia. “The speaker will summarize the ups and downs of these therapies, which are in different stages of clinical trials.”

For patients with medically refractory angina, many therapies involve the same grouping of cells, whether they are taken from a patient’s hip, have been expanded and cultured, or have been filtered, Dr. Allen said.

The last talk, on end-stage congestive heart failure, will go beyond angiogenesis to address the use of cell therapy or stem cells in enhancing and improving heart function, he said.

Return to articles